Chenoweth DE , Cooper SW, Hugli TE et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins . N Engl J Med1981; 304: 497-503.
2.
Butler J., Rocker GM, Westaby S.Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg1993; 55: 552-59.
3.
Dreyer WJ, Michael LH, West MS et al. Neutrophil accumulation in ischemic canine myocardium. Insight into time course, distribution, and mechanism of localization during early reperfusion. Circulation1991; 84: 400-411.
4.
Colman RW, Scott CF, Pixley RA et al. Effect of heparin on the inhibition of contact enzymes. Ann NY Acad Sci1989; 556: 95-103.
5.
Hsu LCPrinciples of heparin coating techniques. Perfusion1991; 6: 209-19.
von Segesser LK, Schilling J., Leskosek B. et al. Surface treatments for perfusion devices . Perfusion1994; 9: 197-205.
8.
Hsu LCDuraflo II heparin immobilized cardiopulmonary bypass circuits. In: Ott RA, Gutfinger DE , Gazzaniga AB eds. Cardiac surgery: state of the art reviews. Philadelphia , Hanley & Belfus, Inc.1993 ; 7: 265-73.
9.
Baier RE, Dutton RCInitial events in interaction of blood with a foreign surface. J Biomed Mater Res1969; 3: 191-206.
10.
Cornelius RM , Brash JLIdentification of proteins adsorbed to hemodialyzer membranes from heparinized plasma. J Biomater Sci Polymer Edn1993; 4: 291-304.
11.
Young BR, Lambrecht LK, Albrecht RM et al. Platelet-protein interactions at blood-polymer interfaces in the canine test model. Trans ASAIO1983; 29: 442-46.
12.
Wendel HP, Heller W., Hoffmeister HEPathway of platelet protection in heparin-coated devices and its significance for cardiovascular surgery. Trans Soc Biomater1995; 21: 281.
Tong SD, Rolfs MR, Hsu LCEvaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits . ASAIO J1990; 36: 654-56.
15.
Gu YJ, van Oeveren W., van der Kamp Kwhj et al. Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion1991; 6: 221-25.
16.
Nakajima T. , Ogawa M., Sasaki T. et al. Clinical study of coagulofibrinolytic system and platelet function with Duraflo II coated cardiopulmonary bypass equipment. ASAIO Abstract1994; 23: 61.
17.
von Segesser LK, Weiss BM, Pasic M. et al. Risk and benefit of low systemic heparinization during open heart operation. Ann Thorac Surg1994; 58: 391-98.
18.
Ovrum E., Holen EA, Tangen G. et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg1995; 60: 365-71.
19.
Ahlvin E., Thelin S., Hagman L. et al. Heparin coated circuits including cardiotomy reservoirs reduces the inflammatory response to cardiopulmonary bypass. 14th Annual San Diego Cardiothoracic Symposium Pathophysiology and Techniques of Cardiopulmonary Bypass, San Diego1994; 14: 236.
20.
van der Kamp Kwhj, van Oeveren W.Contact, coagulation, and platelet interaction with heparin treated equipment during heart surgery. Int J Artif Organs1993; 16: 836-42.
21.
Heller W., Wendel HP, Rifai R. et al. Comparative studies on the haemo- and biocompatibility of a heparin-coated system in aortocoronary bypass surgery. Trans Soc Biomater1995; 21: 282.
22.
Pradhan MJ, Fleming JS, Nkere UU et al. Clinical experience with heparin coated cardiopulmonary bypass circuits. Perfusion1991; 6: 235-42.
23.
Toomasian JM , Hsu LC, Hirschl RB et al. Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Journal1988; 34: 410-14.
24.
von Segesser LK, Weiss BM, von Felton E. et al. Perfusion without systemic heparinization for rewarming in accidental deep hypothermia . Ann Thorac Surg1991; 52: 560-61.
25.
Tong SD, Hsu LCNon-thrombogenic hemofiltration system for acute renal failure treatment. ASAIO Journal1992; 38: M702-M706.
26.
Ovrum E., Brosstad F., Holen EA et al. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation1995; 92: 2579-84.
Gu YJ, van Oeveren W., Akkerman C. et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg1993 ; 55: 917-22.
29.
Jansen Pgm, te Velthuis H., Huybregts Rajm et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits. J Thorac Cardiovasc Surg1995; 110: 829-34.
30.
Moen O., Hogasen K., Andersson C. et al. Changed expression of adhesion molecules on granulocytes, monocytes and thrombocytes in heparin-coated cardiopulmonary bypass. Abstract Scand AssocThorac Surg1995; 26.
31.
Penka M., Hagman L., Halden E. et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg1994 ; 58: 421-24.
32.
Ovrum E., Mollnes TE, Fosse E. et al. High and low systemic heparin doses with completely heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Abstract Scand Assoc Thorac Surg1995; 27.
